[HLA phenotypes in patients surviving a long time after immunotherapy with BCG for acute childhood lymphoblastic leukemia. Arguments in favor of the existance of a gene for immune response in human leukemia].
HLA phenotypes of 13 patients surviving in lasting first remission over 6 years after BCG immunotherapy for acute childhood lymphoblastic leukaemia (ALL) were compared to phenotypes of normal subjects and of surviving ALL patients treated exclusively with chemotherapy. Among the BCG-treated patients, the frequency of the antigen HLA-BW 17 was 46.1% vs 7.3% in healthy controls (p less than 0.001) and the frequency of the antigen HLA-AW 33 was 30.8% vs 1.2% (p less than 0.001). 9 patients possessed at least one of these two antigens (69.2% vs 8% in controls p less than 0.001). Phenotypes of the chemotherapy-treated patients did not differ significantly from controls. These results suggest the existence in humans of HLA-linked genes which are involved in the response to BCG immunotherapy in ALL.
D000293:Adolescent; D001500:BCG Vaccine; D002648:Child; D005802:Genes, MHC Class II; D006680:HLA Antigens / Q000032:analysis*; D006801:Humans; D007167:Immunotherapy; D007945:Leukemia, Lymphoid / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D009163:Mycobacterium bovis; D010641:Phenotype
D001500:BCG Vaccine; D006680:HLA Antigens
Phénotypes HLA des malades survivants à long terme après immunothérapie par le BCG dans la leucémie aiguë lymphoblastique de l'Enfant. Arguments en faveur de l'existence d'un gène de réponse immune dans les leucémies humaines.